Moxifloxacin 0.5% Ophthalmic Solution
- PDF / 184,938 Bytes
- 11 Pages / 504.57 x 720 pts Page_size
- 68 Downloads / 164 Views
ADIS DRUG PROFILE
ª 2011 Adis Data Information BV. All rights reserved.
Moxifloxacin 0.5% Ophthalmic Solution In Bacterial Conjunctivitis Gillian M. Keating Adis, a Wolters Kluwer Business, Auckland, New Zealand
Contents Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1. Pharmacodynamic Profile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. Pharmacokinetic Profile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3. Therapeutic Efficacy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4. Tolerability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5. Dosage and Administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6. Moxifloxacin 0.5% Ophthalmic Solution: Current Status . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abstract The fourth-generation 8-methoxyfluoroquinolone moxifloxacin is available as an 0.5% ophthalmic solution for use in the treatment of bacterial conjunctivitis. Moxifloxacin had good activity against various Gram-positive and -negative ocular isolates in vitro, and moxifloxacin 0.5% ophthalmic solution achieved good penetration into ocular tissues in healthy volunteers and patients undergoing ocular surgery. The efficacy of moxifloxacin 0.5% ophthalmic solution in the treatment of bacterial conjunctivitis has been shown in three randomized, double-blind, multicentre trials. In a trial in patients aged ‡1 year, the clinical success rate was significantly higher with moxifloxacin 0.5% ophthalmic solution than with placebo. In a trial in patients aged ‡12 years, moxifloxacin 0.5% ophthalmic solution was noninferior to levofloxacin 0.5% ophthalmic solution in terms of the clinical success rate. In a third trial, the clinical cure rate was significantly higher with moxifloxacin 0.5% ophthalmic solution than with trimethoprim 1.0%/ polymixin B 10 000 IU/mL ophthalmic solution in paediatric patients aged £18 years. Moxifloxacin 0.5% ophthalmic solution was well tolerated in patients with bacterial conjunctivitis. Ocular adverse events (e.g. eye pain, eye irritation) were the most commonly reported treatment-related adverse events, with the majority being of mild severity.
89 90 94 94 96 97 97
Features and properties of moxifloxacin 0.5% ophthalmic solution (Vigamox®) Indication Topical treatment of purulent bacterial conjunctivitis caused by moxifloxacin-susceptible strains (EU); bacterial conjunctivitis caused by moxifloxacin-susceptible strains (US) Mechanism of action Fluoroquinolone antibacterial
Inhibits the
Data Loading...
